Ritter Pharmaceuticals (NASDAQ:RTTR) Getting Somewhat Critical Press Coverage, Study Finds

Headlines about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat negative this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a news impact score of -0.03 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.7047286219948 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of research analysts have commented on the company. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research note on Tuesday, September 26th. HC Wainwright lowered their target price on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research note on Monday, October 23rd. Finally, Roth Capital set a $2.00 target price on Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $2.10.

Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) traded up $0.02 during trading hours on Wednesday, hitting $0.37. The company’s stock had a trading volume of 841,400 shares, compared to its average volume of 398,330. Ritter Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $3.75. The firm has a market capitalization of $17.82 and a PE ratio of -0.32.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). equities analysts anticipate that Ritter Pharmaceuticals will post -0.38 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Ritter Pharmaceuticals (NASDAQ:RTTR) Getting Somewhat Critical Press Coverage, Study Finds” was first reported by BBNS and is owned by of BBNS. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/ritter-pharmaceuticals-rttr-receives-news-impact-rating-of-0-03/1822872.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.